Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05257551 · ClinicalTrials.gov registry record
Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study
A clinical trial of Small-cell Lung Cancer, sponsored by Tempus AI.
- Recruiting
- Registry status
- 50
- Enrollment target
- 11
- Study locations
NCT05257551 is a study of Small-cell Lung Cancer that is actively recruiting participants, run by Tempus AI. The registered enrollment target is 50 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (78% lower). The trial reports 11 study locations across 9 states.
The verdict
NCT05257551, a study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by Tempus AI.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 11
- Study locations
Study Summary
The study is a non-interventional evaluation of participants with SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA biomarker profiling in addition to their standard of care therapy and disease surveillance.
Conditions Studied
Interventions
- OTHER Observation
Study Locations (11)
Ohio
- TriHealth Cancer Institute - Cincinnati
- Ohio State University - Columbus
- OhioHealth Research Institute - Columbus
California
- Cancer and Blood Specialty Clinic - Los Alamitos
Colorado
- University of Colorado - Aurora
Illinois
- Illinois Cancer Care - Peoria
Maryland
- Johns Hopkins University - Baltimore
New Jersey
- Englewood Health Medical Center - Englewood
North Carolina
- University of North Carolina - Chapel Hill
Oklahoma
- Oklahoma Cancer Specialists and Research Institutes - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-07-13 |
| Est. Completion | 2029-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05257551
The ClinicalTrials.gov registry entry for NCT05257551 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Tempus AI, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.
NCT05257551 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Ohio, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05257551 about?
NCT05257551 is a clinical study titled "Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study". The study is a non-interventional evaluation of participants with SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA biomarker profiling in addition to their standard of care therapy and disease surveillance.
What is the current status of trial NCT05257551?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2022-07-13. Estimated completion is 2029-03.
What conditions does trial NCT05257551 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT05257551?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT05257551?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05257551 being conducted?
This trial has 11 study locations across California, Colorado, Illinois, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
RECRUITING
-
A Study of Hospital-at-Home for People Receiving Tarlatamab
RECRUITING · NA
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.